# Lightpath Technologies Inc: financial statements, quarterly

LPTH · Nasdaq · CIK 889971 · [Technology](/sectors/technology.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/lpth.md) · [Financials](/companies/lpth/financials.md) · [Filings](/companies/lpth/filings.md) · [Insiders](/companies/lpth/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lpth/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [8.1](/filings/0001654954-24-013931.md) | [7.3](/filings/0001654954-25-001434.md) | [7.7](/filings/0001654954-25-005945.md) | [8.6 d](/filings/0001654954-25-011130.md) | [8.4](/filings/0001654954-25-012804.md) | [7.4](/filings/0001654954-25-001434.md) | [9.2](/filings/0001654954-25-005945.md) | [12.2 d](/filings/0001654954-25-011130.md) | [15.1](/filings/0001654954-25-012804.md) | [16.4](/filings/0001437749-26-003809.md) | [19.1](/filings/0001437749-26-015594.md) | [21.2 d](/filings/0001437749-26-030106.md) |
| Cost of revenue | $m | [5.7](/filings/0001654954-24-013931.md) | [5.1](/filings/0001654954-25-001434.md) | [6.1](/filings/0001654954-25-005945.md) | [6.1 d](/filings/0001654954-25-011130.md) | [5.6](/filings/0001654954-25-012804.md) | [5.5](/filings/0001654954-25-001434.md) | [6.5](/filings/0001654954-25-005945.md) | [9.5 d](/filings/0001654954-25-011130.md) | [10.6](/filings/0001654954-25-012804.md) | [10.3](/filings/0001437749-26-003809.md) | [12.2](/filings/0001437749-26-015594.md) | [12.8 d](/filings/0001437749-26-030106.md) |
| Gross profit | $m | [2.3](/filings/0001654954-24-013931.md) | [2.2](/filings/0001654954-25-001434.md) | [1.6](/filings/0001654954-25-005945.md) | [2.5 d](/filings/0001654954-25-011130.md) | [2.8](/filings/0001654954-25-012804.md) | [1.9](/filings/0001437749-26-003809.md) | [2.7](/filings/0001437749-26-015594.md) | [2.7 d](/filings/0001437749-26-030106.md) | [4.5](/filings/0001654954-25-012804.md) | [6.0](/filings/0001437749-26-003809.md) | [7.0](/filings/0001437749-26-015594.md) | [8.3 d](/filings/0001437749-26-030106.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | [0.8](/filings/0001437749-26-003809.md) | [0.8](/filings/0001437749-26-015594.md) | [1.1 d](/filings/0001437749-26-030106.md) | not reported | [0.7](/filings/0001437749-26-003809.md) | [1.0](/filings/0001437749-26-015594.md) | [1.1 d](/filings/0001437749-26-030106.md) |
| Selling, general and administrative | $m | [2.7](/filings/0001654954-24-013931.md) | [2.9](/filings/0001654954-25-001434.md) | [3.2](/filings/0001654954-25-005945.md) | [3.6 d](/filings/0001654954-25-011130.md) | [3.3](/filings/0001654954-25-012804.md) | [3.4](/filings/0001437749-26-003809.md) | [4.4](/filings/0001437749-26-015594.md) | [4.7 d](/filings/0001437749-26-030106.md) | [4.4](/filings/0001654954-25-012804.md) | [5.9](/filings/0001437749-26-003809.md) | [6.3](/filings/0001437749-26-015594.md) | [8.1 d](/filings/0001437749-26-030106.md) |
| Operating income | $m | [(1.3)](/filings/0001654954-24-013931.md) | [(1.8)](/filings/0001654954-25-001434.md) | [(2.6)](/filings/0001654954-25-005945.md) | [(2.2) d](/filings/0001654954-25-011130.md) | [(1.4)](/filings/0001654954-25-012804.md) | [(2.5)](/filings/0001437749-26-003809.md) | [(3.5)](/filings/0001437749-26-015594.md) | [(4.5) d](/filings/0001437749-26-030106.md) | [(2.5)](/filings/0001654954-25-012804.md) | [(8.6)](/filings/0001437749-26-003809.md) | [(4.3)](/filings/0001437749-26-015594.md) | [(4.3) d](/filings/0001437749-26-030106.md) |
| Interest expense | $m | [0.1](/filings/0001654954-24-013931.md) | [0.1](/filings/0001654954-25-001434.md) | [0.0](/filings/0001654954-25-005945.md) | [0.0 d](/filings/0001654954-25-011130.md) | [0.1](/filings/0001654954-25-012804.md) | [0.2](/filings/0001654954-25-001434.md) | [0.5](/filings/0001654954-25-005945.md) | [0.3 d](/filings/0001654954-25-011130.md) | [0.3](/filings/0001654954-25-012804.md) | [0.3](/filings/0001437749-26-003809.md) | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001654954-24-013931.md) | [0.1](/filings/0001654954-25-001434.md) | [0.0](/filings/0001654954-25-005945.md) | [(0.1) d](/filings/0001654954-25-011130.md) | [0.0](/filings/0001654954-25-012804.md) | [0.0](/filings/0001437749-26-003809.md) | [0.1](/filings/0001437749-26-015594.md) | [(0.1) d](/filings/0001437749-26-030106.md) | [0.1](/filings/0001654954-25-012804.md) | [0.0](/filings/0001437749-26-003809.md) | [0.1](/filings/0001437749-26-015594.md) | [0.1 d](/filings/0001437749-26-030106.md) |
| Net income | $m | [(1.3)](/filings/0001654954-25-005945.md) | [(1.7)](/filings/0001654954-25-005945.md) | [(2.6)](/filings/0001654954-25-005945.md) | [(2.4) d](/filings/0001654954-25-011130.md) | [(1.6)](/filings/0001437749-26-015594.md) | [(2.6)](/filings/0001437749-26-015594.md) | [(3.6)](/filings/0001437749-26-015594.md) | [(7.1) d](/filings/0001437749-26-030106.md) | [(2.9)](/filings/0001437749-26-015594.md) | [(9.4)](/filings/0001437749-26-015594.md) | [(4.1)](/filings/0001437749-26-015594.md) | [(4.1) d](/filings/0001437749-26-030106.md) |
| Diluted EPS | $ per share | [(0.04)](/filings/0001654954-24-013931.md) | [0.05](/filings/0001654954-25-001434.md) | [(0.07)](/filings/0001654954-25-005945.md) | not reported | [(0.04)](/filings/0001654954-25-012804.md) | [(0.07)](/filings/0001437749-26-003809.md) | [(0.09)](/filings/0001437749-26-015594.md) | not reported | [(0.07)](/filings/0001654954-25-012804.md) | [(0.20)](/filings/0001437749-26-003809.md) | [(0.07)](/filings/0001437749-26-015594.md) | not reported |
| Basic EPS | $ per share | [(0.04)](/filings/0001654954-24-013931.md) | [0.05](/filings/0001654954-25-001434.md) | [(0.07)](/filings/0001654954-25-005945.md) | not reported | [(0.04)](/filings/0001654954-25-012804.md) | [(0.07)](/filings/0001437749-26-003809.md) | [(0.09)](/filings/0001437749-26-015594.md) | not reported | [(0.07)](/filings/0001654954-25-012804.md) | [(0.20)](/filings/0001437749-26-003809.md) | [(0.07)](/filings/0001437749-26-015594.md) | not reported |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue, us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.3](/filings/0001654954-23-014011.md) | [3.5](/filings/0001654954-24-001495.md) | [3.0](/filings/0001654954-24-005881.md) | [3.5](/filings/0001654954-25-005945.md) | [4.3](/filings/0001654954-24-013931.md) | [3.2](/filings/0001654954-25-001434.md) | [6.5](/filings/0001654954-25-005945.md) | [4.9](/filings/0001437749-26-030106.md) | [11.5](/filings/0001654954-25-012804.md) | [73.6](/filings/0001437749-26-003809.md) | [55.2](/filings/0001437749-26-015594.md) | [93.2](/filings/0001437749-26-030106.md) |
| Current assets | $m | [20.0](/filings/0001654954-23-014011.md) | [18.8](/filings/0001654954-24-001495.md) | [15.5](/filings/0001654954-24-005881.md) | [15.5](/filings/0001654954-25-011130.md) | [16.8](/filings/0001654954-24-013931.md) | [15.6](/filings/0001654954-25-001434.md) | [28.1](/filings/0001654954-25-005945.md) | [28.4](/filings/0001437749-26-030106.md) | [35.2](/filings/0001654954-25-012804.md) | [97.0](/filings/0001437749-26-003809.md) | [83.0](/filings/0001437749-26-015594.md) | [130](/filings/0001437749-26-030106.md) |
| Total assets | $m | [55.3](/filings/0001654954-23-014011.md) | [54.1](/filings/0001654954-24-001495.md) | [49.7](/filings/0001654954-24-005881.md) | [48.1](/filings/0001654954-25-011130.md) | [48.4](/filings/0001654954-24-013931.md) | [45.8](/filings/0001654954-25-001434.md) | [81.4](/filings/0001654954-25-005945.md) | [81.5](/filings/0001437749-26-030106.md) | [87.3](/filings/0001654954-25-012804.md) | [149](/filings/0001437749-26-003809.md) | [144](/filings/0001437749-26-015594.md) | [194](/filings/0001437749-26-030106.md) |
| Current liabilities | $m | [8.5](/filings/0001654954-23-014011.md) | [9.7](/filings/0001654954-24-001495.md) | [7.7](/filings/0001654954-24-005881.md) | [8.0](/filings/0001654954-25-011130.md) | [9.7](/filings/0001654954-24-013931.md) | [10.2](/filings/0001654954-25-001434.md) | [12.2](/filings/0001654954-25-005945.md) | [17.1](/filings/0001437749-26-030106.md) | [17.8](/filings/0001654954-25-012804.md) | [24.4](/filings/0001437749-26-003809.md) | [21.5](/filings/0001437749-26-015594.md) | [26.2](/filings/0001437749-26-030106.md) |
| Total liabilities | $m | [20.4](/filings/0001654954-23-014011.md) | [20.4](/filings/0001654954-24-001495.md) | [18.0](/filings/0001654954-24-005881.md) | [17.9](/filings/0001654954-25-011130.md) | [19.0](/filings/0001654954-24-013931.md) | [19.1](/filings/0001654954-25-001434.md) | [31.3](/filings/0001654954-25-005945.md) | [31.6](/filings/0001437749-26-030106.md) | [31.6](/filings/0001654954-25-012804.md) | [36.4](/filings/0001437749-26-003809.md) | [31.4](/filings/0001437749-26-015594.md) | [35.6](/filings/0001437749-26-030106.md) |
| Long-term debt | $m | [1.2](/filings/0001654954-23-014011.md) | [0.3](/filings/0001654954-24-001495.md) | [0.3](/filings/0001654954-24-005881.md) | [0.3](/filings/0001654954-24-012103.md) | [0.3](/filings/0001654954-24-013931.md) | [0.2](/filings/0001654954-25-001434.md) | [4.7](/filings/0001654954-25-005945.md) | [4.8](/filings/0001654954-25-011130.md) | [4.9](/filings/0001654954-25-012804.md) | not reported | not reported | not reported |
| Shareholders' equity | $m | [34.9](/filings/0001654954-25-005945.md) | [33.7](/filings/0001654954-25-005945.md) | [31.7](/filings/0001654954-25-005945.md) | [30.2](/filings/0001437749-26-030106.md) | [29.4](/filings/0001437749-26-015594.md) | [26.7](/filings/0001437749-26-015594.md) | [15.7](/filings/0001437749-26-015594.md) | [15.6](/filings/0001437749-26-030106.md) | [21.4](/filings/0001437749-26-015594.md) | [77.9](/filings/0001437749-26-015594.md) | [89.1](/filings/0001437749-26-015594.md) | [149](/filings/0001437749-26-030106.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [1,140](/filings/0001654954-24-013931.md) | [(289) d](/filings/0001654954-25-001434.md) | [(394) d](/filings/0001654954-25-005945.md) | [64.7 d](/filings/0001654954-25-011130.md) | [(1,700)](/filings/0001654954-25-012804.md) | [(737) d](/filings/0001437749-26-003809.md) | [(3,244) d](/filings/0001437749-26-015594.md) | [(2,650) d](/filings/0001437749-26-030106.md) | [(1,143)](/filings/0001654954-25-012804.md) | [2,824 d](/filings/0001437749-26-003809.md) | [(6,798) d](/filings/0001437749-26-015594.md) | [(5,109) d](/filings/0001437749-26-030106.md) |
| Capital expenditure | $k | [955](/filings/0001654954-24-013931.md) | [529 d](/filings/0001654954-25-001434.md) | [408 d](/filings/0001654954-25-005945.md) | [290 d](/filings/0001654954-25-011130.md) | [79.7](/filings/0001654954-25-012804.md) | [80.4 d](/filings/0001437749-26-003809.md) | [421 d](/filings/0001437749-26-015594.md) | [682 d](/filings/0001437749-26-030106.md) | [77.0](/filings/0001654954-25-012804.md) | [868 d](/filings/0001437749-26-003809.md) | [899 d](/filings/0001437749-26-015594.md) | [4,424 d](/filings/0001437749-26-030106.md) |
| Share repurchases | $k | [0.0](/filings/0001654954-23-014011.md) | [0.0](/filings/0001654954-24-001495.md) | [0.0](/filings/0001654954-24-005881.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [27.1](/filings/0001654954-23-014011.md) | [27.2](/filings/0001654954-24-001495.md) | [35.1](/filings/0001654954-24-005881.md) | [37.4](/filings/0001654954-24-013931.md) | [37.5](/filings/0001654954-25-001434.md) | [38.0](/filings/0001654954-25-005945.md) | [39.6](/filings/0001654954-25-012804.md) | [39.7](/filings/0001437749-26-003809.md) | [41.4](/filings/0001437749-26-015594.md) | [43.3](/filings/0001654954-25-012804.md) | [47.0](/filings/0001437749-26-003809.md) | [58.6](/filings/0001437749-26-015594.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 70,036,252 at 2026-09-08, from the cover of the [10-K filed 2026-09-11](/filings/0001437749-26-030106.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.